logo-loader
ANGLE PLC

ANGLE device could receive US regulatory sign-off early next year after breast cancer trial success

Boss Andrew Newland said: “This clearance, considered the gold standard for approval of medical diagnostic systems globally, would further competitively differentiate the Parsortix system and should lead to an acceleration in commercial adoption of the system in both research and clinical settings.”

blood in vials
The company's device can harvest cancer cells from blood

ANGLE PLC (LON:AGL) is on track to gain US regulatory certification for its liquid biopsy system early next year after a clinical trial of 400 women with breast cancer met its primary objectives.

The med-tech firm is seeking Food & Drug Administration Class II regulatory clearance for its Parsortix technology that harvests circulating tumour cells, which provide the tell-tale signs of cancer. FDA sign-off is seen as the gold standard for a medical device.

The assessment itself revealed Parsortix was able to harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients.

It also achieved exploratory goals such as being able to “interrogate” patient blood using certain analysis techniques.

Additional experiments 

In discussions with the FDA, the regulator has identified certain additional experiments that should be carried out. ANGLE said they are of “minimal cost” and will allow its researchers to submit Parsortix data early in the fourth quarter, meaning it could potentially receive its certification in early 2020.

“We are working to complete the remaining analytical study work and the full data analysis and interpretation so that an FDA submission can be made as soon as possible,” said chief executive Andrew Newland.

"We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer.

“This clearance, considered the gold standard for approval of medical diagnostic systems globally, would further competitively differentiate the Parsortix system and should lead to an acceleration in commercial adoption of the system in both research and clinical settings.”

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £122.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Endorsement for Angle's liquid biopsy system Parsortix

Top stories from the Proactive Investors UK newsroom. Angle (LON:AGL) has received an endorsement for its liquid biopsy system Parsortix from European cancer centre UKE, which says it has potential as a biomarker to test for lung cancer. Security group Westminster (LON:WSG) has signed...

on 21/6/19

2 min read